# OnCo record relapsed-refractory-hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "relapsed-refractory-hodgkin-lymphoma" ;
  schema:name "Relapsed and refractory classical Hodgkin lymphoma"@en ;
  schema:alternateName "Relapsed Hodgkin lymphoma"@en, "Refractory Hodgkin lymphoma"@en, "R/R cHL"@en, "Hodgkin lymphoma after first-line failure"@en ;
  schema:description "Relapsed or refractory classical Hodgkin lymphoma is Hodgkin lymphoma that comes back or does not respond after first-line chemotherapy. The standard path is salvage chemotherapy, often with brentuximab vedotin or a PD-1 antibody, then high-dose chemotherapy with an autologous stem cell transplant; for those who relapse again, nivolumab and pembrolizumab give lasting control in many."@en ;
  schema:url <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)60165-9>, <https://doi.org/10.1016/S1470-2045(21)00005-X>, <https://en.wikipedia.org/wiki/Hodgkin_lymphoma>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/stem-cell-transplants/self-autologous-stem-cell>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/lymphoma-comes-back-relapses-or-doesnt-respond>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/car-t-cell-therapy>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/late-effects-lymphoma-treatment> ;
  onco:tag "subtype-page", "haematologic" ;
  onco:related <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/> ;
  onco:targets <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/everolimus/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-hodgkin-late-effects/>, <https://onco.cc/terms/lymphoma-tx-fertility-preservation/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/terms/lymphoma-tx-uk-versus-us/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-local-or-car-t-centre/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-living-hodgkin-survivorship-screening/>, <https://onco.cc/terms/lymphoma-living-infection-years-after/>, <https://onco.cc/terms/lymphoma-living-fatigue/> ;
  onco:trials <https://onco.cc/trials/aethera/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/trials/nct04268706/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/>, <https://onco.cc/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/>, <https://onco.cc/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/> ;
  onco:pipeline <https://onco.cc/trials/nct04268706/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/> ;
  onco:standardOfCare <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/trials/aethera/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/penpulimab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/trials/nct04268706/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/aethera/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/>, <https://onco.cc/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/palliative-radiotherapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/> .